Please assess the completion status of the following clinical trial:

Trial Title: TachoSil® Versus Standard Haemostatic Treatment of Haemorrhage in Cardiovascular Surgery (TC-023-IM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All inclusion criteria must be answered yes for a subject to participate in the trial.~At Screening:~1. Has the subject given informed consent according to local requirements before any trial related activities? A trial related activity is any procedure that would not have been performed during the routine management of the subject. In this trial the screening is the first trial related activity.~2. For female subjects of childbearing potential: Is the pregnancy test at screening negative?~3. Does the female subject of childbearing potential use adequate contraception (contraceptive pill, contraceptive injection, contraceptive implant or intrauterine device)?~4. Is the subject ≥ 18 years of age?~5. Is the following planned: An elective surgery on the heart, the ascending aorta or arch, requiring cardiopulmonary bypass procedure?~   Intra operative (after primary haemostatic treatment):~6. Is bleeding from the heart muscle, the pericardium, a major vessel or a vascular bed that requires supportive haemostatic treatment present?~7. Has the area with the most problematic haemorrhage (target area) been identified? (please note that this must be done before randomisation).~8. Is it possible to compress the randomised treatment (TachoSil® or control fleece material) for 3 minutes?~Exclusion Criteria:~All exclusion criteria must be answered no for a subject to participate in the trial.~At Screening:~1. Has the subject participated in any other trial with an investigational drug or device within 30 days before inclusion in this trial?~2. Does the subject participate in a clinical trial concomitantly with the present trial?~3. Is the subject undergoing an emergency operation?~4. Has the subject a history of allergic reactions after application of human fibrinogen, human thrombin and/or collagen of any origin?~5. Is the subject suffering from known coagulopathy?~6. Is the subject currently participating or has the subject previously participated in the TC-023-IM trial?~7. Is the female subject pregnant or breast feeding?~   Intra operative (after primary haemostatic treatment):~8. Has liquid fibrin sealant/glue or TachoSil® been applied?~9. Has the following occurred: Disseminated intravascular coagulation (DIC), i.e. micro vascular bleeding?

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TachoSil® (Type: ACTIVE_COMPARATOR): None
- Standard Treatment (Type: ACTIVE_COMPARATOR): Standard Treatment of haemorrhage in cardiovascular surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).